Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients
- PMID: 12469360
- DOI: 10.1002/dmrr.325
Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients
Abstract
Background: Cyclosporin A (CyA) may induce acute nephrotoxicity. The question has been raised of the possible long-term unfavorable course of CyA-induced lesions. Advantage was taken of a large cohort of diabetic patients treated for several months using moderate CyA dosage to evaluate the long-term evolution of renal function in such patients.
Methods: Two hundred and eighty five recently diagnosed type 1 diabetic patients having received CyA for a mean of 19.9 months were monitored for 13 years, in parallel with 100 similar patients treated with insulin alone.
Results: In the CyA-treated group, a transient increase in creatininemia levels occurred during the first 18 months of treatment associated with a transient increase in renal vascular resistance. Both effects disappeared later on: creatininemia levels then remained normal. Inulin and p-aminohippurate (PAH) clearances remained normal throughout follow-up. Neither permanent renal failure nor progressive deterioration of renal function occurred in either group or in individual patients. A 10 to 12% increase in inulin and PAH clearance was elicited by IV amino acid infusion at 7 to 10 years, a finding consistent with a normal renal functional reserve. Patients with moderate kidney lesions on biopsy at 1 year had normal and stable clearance values at 7 to 13 years. The prevalence of arterial hypertension and retinopathy was lower in the CyA-treated group than in the control group, possibly because of the tighter metabolic control obtained in the CyA group.
Conclusion: These results suggest that low-dose CyA treatment combined with thorough monitoring does not result in long-term renal dysfunction.
Copyright 2002 John Wiley & Sons, Ltd.
Similar articles
-
The kidney in cyclosporin A-treated diabetic patients: a long-term clinicopathological study.Clin Nephrol. 1994 Jan;41(1):41-9. Clin Nephrol. 1994. PMID: 8137568
-
Effects of STZ-induced diabetes and its treatment with vanadyl sulphate on cyclosporine A-induced nephrotoxicity in rats.Arch Toxicol. 2005 Sep;79(9):493-9. doi: 10.1007/s00204-005-0663-7. Epub 2005 Jun 7. Arch Toxicol. 2005. PMID: 15940472
-
Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. doi: 10.1093/ndt/gfh957. Epub 2005 Jun 28. Nephrol Dial Transplant. 2005. PMID: 15985508
-
Cyclosporin A nephropathy in patients with rheumatoid arthritis.Br J Rheumatol. 1993 Mar;32 Suppl 1:60-4. Br J Rheumatol. 1993. PMID: 8448641 Review.
-
Cyclosporine: from renal transplantation to autoimmune diseases.Ann N Y Acad Sci. 2005 Jun;1051:551-8. doi: 10.1196/annals.1361.099. Ann N Y Acad Sci. 2005. PMID: 16126995 Review.
Cited by
-
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.Islets. 2013 Mar-Apr;5(2):53-66. doi: 10.4161/isl.24785. Epub 2013 Mar 1. Islets. 2013. PMID: 23648893 Free PMC article. Review.
-
Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials.Rev Diabet Stud. 2005 Fall;2(3):116-20. doi: 10.1900/RDS.2005.2.116. Epub 2005 Nov 10. Rev Diabet Stud. 2005. PMID: 17491686 Free PMC article. No abstract available.
-
Proposal for generating new beta cells in a muted immune environment for type 1 diabetes.Diabetes Metab Res Rev. 2013 Nov;29(8):604-6. doi: 10.1002/dmrr.2435. Diabetes Metab Res Rev. 2013. PMID: 23853103 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical